Journal of the American Society of Nephrology, Vol 6, 110-120, Copyright © 1995 by American Society of Nephrology

REGULAR ARTICLES

Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis

F Kronenberg, P Konig, U Neyer, M Auinger, A Pribasnig, U Lang, J Reitinger, G Pinter, G Utermann and H Dieplinger
Institute of Medical Biology and Human Genetics, University of Innsbruck, Austria.

Numerous studies have investigated lipoprotein(a) (Lp(a)) plasma concentrations in patients with ESRD, a patient group with an enormous risk for atherosclerosis. The reported differences in Lp(a) between controls and patients vary from a decrease of 49% to an increase of more than 1,000%. However, data are not consistent, mostly because of problems with statistical analysis, and only limited data are available for patients treated by continuous ambulatory peritoneal dialysis (CAPD). To estimate the significance of Lp(a) in ESRD and to demonstrate the statistical pitfalls concerning Lp(a) in case-control studies, a large multicenter study including 702 patients treated by either hemodialysis (HD) (N = 534) or CAPD (N = 168) was conducted, and results were compared with results from 256 healthy controls. Both patient groups showed significantly elevated Lp(a) levels in comparison with controls: 23.4 +/- 25.0 mg/dL (P < 0.005; HD) and 34.6 +/- 38.4 mg/dL (P < 0.0001; CAPD) versus 18.4 +/- 22.8 mg/dL (controls). CAPD patients showed significantly higher Lp(a) values than did patients treated by HD (P < 0.001). The difference between the two treatment groups possibly reflects an overproduction of Lp(a) to compensate for protein losses in CAPD patients. Both treatment groups included significantly more patients with Lp(a) values greater than the 75th percentile (25.6 mg/dL) of the control group (33.9 and 41.7% for HD and CAPD, respectively; P < 0.005). The higher Lp(a) values in patients were not explained by differences in isoform frequencies and the increase in Lp(a) was apolipoprotein(a) type specific: only patients with high-molecular-weight apolipoprotein(a) isoforms showed a significant elevation in Lp(a) levels. The increased plasma concentrations of Lp(a) may contribute to the high risk for atherosclerosis in ESRD, especially in patients treated by CAPD. Finally, it is believed that small sample sizes are responsible for the diverging results in Lp(a) literature.

This article has been cited by other articles:

				M. S Joy, K. A Dornbrook-Lavender, H. Chin, S. L Hogan, and C. Denu-Ciocca Effects of Atorvastatin on Lp(a) and Lipoprotein Profiles in Hemodialysis Patients Ann. Pharmacother., January 1, 2008; 42(1): 9 - 15. [Abstract] [Full Text] [PDF]

				J. Nogueira and M. Weir The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 766 - 785. [Abstract] [Full Text] [PDF]

				B. C.H. Kwan, F. Kronenberg, S. Beddhu, and A. K. Cheung Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1246 - 1261. [Full Text] [PDF]

				R.-E. W. Kavey, V. Allada, S. R. Daniels, L. L. Hayman, B. W. McCrindle, J. W. Newburger, R. S. Parekh, and J. Steinberger Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics Circulation, December 12, 2006; 114(24): 2710 - 2738. [Abstract] [Full Text] [PDF]

				J-P Chretien, J Coresh, Y Berthier-Schaad, W H L Kao, N E Fink, M J Klag, S M Marcovina, F Giaculli, and M W Smith Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans J. Med. Genet., December 1, 2006; 43(12): 917 - 923. [Abstract] [Full Text] [PDF]

				A. Lingenhel, K. Lhotta, U. Neyer, I. M. Heid, B. Rantner, M. F. Kronenberg, P. Konig, A. von Eckardstein, M. Schober, H. Dieplinger, et al. Role of the kidney in the metabolism of apolipoprotein A-IV: influence of the type of proteinuria J. Lipid Res., September 1, 2006; 47(9): 2071 - 2079. [Abstract] [Full Text] [PDF]

				B. Kollerits, M. Auinger, V. Reisig, T. Kastenbauer, A. Lingenhel, K. Irsigler, R. Prager, and F. Kronenberg Lipoprotein(a) as a Predictor of Cardiovascular Disease in a Prospectively Followed Cohort of Patients With Type 1 Diabetes Diabetes Care, July 1, 2006; 29(7): 1661 - 1663. [Full Text] [PDF]

				E. Boes, D. Fliser, E. Ritz, P. Konig, K. Lhotta, J. F.E. Mann, G. A. Muller, U. Neyer, W. Riegel, P. Riegler, et al. Apolipoprotein A-IV Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease Study J. Am. Soc. Nephrol., February 1, 2006; 17(2): 528 - 536. [Abstract] [Full Text] [PDF]

				K. Ikewaki, J. R. Schaefer, M. E. Frischmann, K. Okubo, T. Hosoya, S. Mochizuki, B. Dieplinger, E. Trenkwalder, H. Schweer, F. Kronenberg, et al. Delayed In Vivo Catabolism of Intermediate-Density Lipoprotein and Low-Density Lipoprotein in Hemodialysis Patients as Potential Cause of Premature Atherosclerosis Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2615 - 2622. [Abstract] [Full Text] [PDF]

				K.-H. Song, S. H. Ko, H.-W. Kim, Y.-B. Ahn, J.-M. Lee, H.-S. Son, K.-H. Yoon, B.-Y. Cha, K.-W. Lee, and H.-Y. Son Prospective Study of Lipoprotein(a) as a Risk Factor for Deteriorating Renal Function in Type 2 Diabetic Patients With Overt Proteinuria Diabetes Care, July 1, 2005; 28(7): 1718 - 1723. [Abstract] [Full Text] [PDF]

				J. C. Longenecker, M. J. Klag, S. M. Marcovina, Y.-M. Liu, B. G. Jaar, N. R. Powe, N. E. Fink, A. S. Levey, and J. Coresh High Lipoprotein(a) Levels and Small Apolipoprotein(a) Size Prospectively Predict Cardiovascular Events in Dialysis Patients J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1794 - 1802. [Abstract] [Full Text] [PDF]

				D. S. Parsons, D. A. Reaveley, D. V. Pavitt, M. Misra, and E. A. Brown Lipoprotein (a) levels in those with high molecular weight apo (a) isoforms may remain low in a significant proportion of patients with end-stage renal disease Nephrol. Dial. Transplant., September 1, 2003; 18(9): 1848 - 1853. [Abstract] [Full Text] [PDF]

				S. S. Prichard Impact of Dyslipidemia in End-Stage Renal Disease J. Am. Soc. Nephrol., September 1, 2003; 14(90004): S315 - 320. [Abstract] [Full Text]

				J. C. Longenecker, M. J. Klag, S. M. Marcovina, N. R. Powe, N. E. Fink, F. Giaculli, and J. Coresh Small Apolipoprotein(a) Size Predicts Mortality in End-Stage Renal Disease: The CHOICE Study Circulation, November 26, 2002; 106(22): 2812 - 2818. [Abstract] [Full Text] [PDF]

				F. Kronenberg, E. Kuen, E. Ritz, P. Konig, G. Kraatz, K. Lhotta, J. F. E. Mann, G. A. Muller, U. Neyer, W. Riegel, et al. Apolipoprotein A-IV Serum Concentrations Are Elevated in Patients with Mild and Moderate Renal Failure J. Am. Soc. Nephrol., February 1, 2002; 13(2): 461 - 469. [Abstract] [Full Text] [PDF]

				F. WAHN, V. DANIEL, F. KRONENBERG, G. OPELZ, D. V. MICHALK, and U. QUERFELD Impact of Apolipoprotein(a) Phenotypes on Long-Term Renal Transplant Survival J. Am. Soc. Nephrol., May 1, 2001; 12(5): 1052 - 1058. [Abstract] [Full Text]

				F. Locatelli, J. Bommer, G. M. London, A. Martin-Malo, C. Wanner, M. Yaqoob, and C. Zoccali Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment Nephrol. Dial. Transplant., March 1, 2001; 16(3): 459 - 468. [Abstract] [Full Text] [PDF]

				P. Stenvinkel, B. Lindholm, M. Heimburger, and O. Heimburger Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease Nephrol. Dial. Transplant., October 1, 2000; 15(10): 1624 - 1630. [Abstract] [Full Text] [PDF]

				M. FUJISAWA, R. HARAMAKI, H. MIYAZAKI, T. IMAIZUMI, and S. OKUDA Role of Lipoprotein (a) and TGF-{beta}1 in Atherosclerosis of Hemodialysis Patients J. Am. Soc. Nephrol., October 1, 2000; 11(10): 1889 - 1895. [Abstract] [Full Text]

				F. Kronenberg, M. Stuhlinger, E. Trenkwalder, F. S. Geethanjali, O. Pachinger, A. von Eckardstein, and H. Dieplinger Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease J. Am. Coll. Cardiol., September 1, 2000; 36(3): 751 - 757. [Abstract] [Full Text] [PDF]

				H. J Milionis, A. F Winder, and D. P Mikhailidis Lipoprotein (a) and stroke J. Clin. Pathol., July 1, 2000; 53(7): 487 - 496. [Abstract] [Full Text] [PDF]

				V. Mooser, M. M. Berger, L. Tappy, C. Cayeux, S. M. Marcovina, R. Darioli, P. Nicod, and R. Chiolero Major Reduction in Plasma Lp(a) Levels During Sepsis and Burns Arterioscler. Thromb. Vasc. Biol., April 1, 2000; 20(4): 1137 - 1142. [Abstract] [Full Text] [PDF]

				F. KRONENBERG, E. KUEN, E. RITZ, R. JUNKER, P. KÖNIG, G. KRAATZ, K. LHOTTA, J. F. E. MANN, G. A. MÜLLER, U. NEYER, et al. Lipoprotein(a) Serum Concentrations and Apolipoprotein(a) Phenotypes in Mild and Moderate Renal Failure J. Am. Soc. Nephrol., January 1, 2000; 11(1): 105 - 115. [Abstract] [Full Text]

				M. S. Elisaf, H. J. Millionis, and K. C. Siamopoulos Increased Serum Lipoprotein(a) Levels in Patients with Early Renal Failure Ann Intern Med, June 15, 1999; 130(12): 1028 - 1028. [Full Text] [PDF]

				F. KRONENBERG, U. NEYER, K. LHOTTA, E. TRENKWALDER, M. AUINGER, A. PRIBASNIG, T. MEISL, P. KÖNIG, and H. DIEPLINGER The Low Molecular Weight Apo(a) Phenotype Is an Independent Predictor for Coronary Artery Disease in Hemodialysis Patients: A ProspectiveFollow-Up J. Am. Soc. Nephrol., May 1, 1999; 10(5): 1027 - 1036. [Abstract] [Full Text]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673